The HDAC inhibitor vorinostat is approved for the treatment of cutaneous T cell lymphoma, and is currently being trialled in combination with other agents, including immune checkpoint inhibitors, for the treatment of several other cancers [46]. The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.